Six "first-in-class" new drugs to help Soryuan Bio completed nearly 600 million yuan C round of financing.

Founded in 2012, Soyuan Bio is a new precision medicine company that develops the world's first innovative drug in a fast and effective way, with Dr. Rowan as CEO and Chief Scientist.
since its inception, so yuan biology has been favored by many capitals.
earlier this year, the company completed a 300 million yuan B round of financing, with the participation of Kuyou Capital, Xianyu Capital, Shared Capital, Zhejiang Commercial Production and Finance, Yuexiu Capital, Qianzhen Capital and Wenfang Technology.
October 2019, SSE announced the launch of pre-IPO financing.
's research and development strategy is to introduce new drugs from major international pharmaceutical companies that have been shown to be safe and effective in some patients through late-stage clinical trials, and then to use its original biomarker platform technology to find biomarkers that predict drug efficacy in residual clinical samples.
Screening patients with these newly discovered biomarkers as accompanying diagnostics enables the re-run of clinical trials in sensitive patients to optimize efficacy, safety and tolerance, and increase the success rate of new drug development, thereby achieving the goal of developing innovative drugs at a lower cost and in a shorter time.
, so far, Soryuan Bio has a global interest in six of the world's first-in-class drugs developed into clinical late stages, namely DB102, DB103, DB104, DB105, DB106 and DB107, covering Oncology and psychosis: DB102 (enzastaurin) was originally developed for Eli Lilly and Company to treat primary treatment of high-risk diffuse large B-cell lymphoma (DLBCL) and cerebral glioblastoma (GBM).
using its reverse all-gene scanning platform technology to complete a large-scale genomics analysis of samples from the Phase 3 PRELUDE clinical trial of DB102, a new set of biomarkers DGM1, DGM1-positive patients with a very significant improvement in survival after taking DB102.
based on the above findings, Soryuan Bio has initiated and conducted an international multi-center Clinical Phase 3 trial (ENGINE study), which has now completed more than 90% of the patients in the group.
multi-center clinical trial of DB102 for the treatment of newly diagnosed GBM has also been approved by the FDA and China's National Drug Administration (NMPA) and will be launched this year.
103 (pomaglumetad) was originally developed for Lilly to treat schizophrenia.
liafensine was originally developed for ARMI/BMS to treat depression.
DB105 was developed for the Finnish Olathe Group to treat Alzheimer's disease.
DB106 was originally developed for Sunes pharmaceutical company in the United States for the treatment of acute myeloid leukemia.
DB107 was originally developed for Tocagen to treat relapsed high-level gliomas.
addition to the acquisition of DB107, Soryuan Bio also has a global interest in Tocagen's RRV gene therapy platform. Dr Rowan, Chairman of
Soyuan Bio, said: "Over the past year, Soryuan Bio has come a long way, doubles its research and development pipeline and now has a global interest in six innovative clinical 2b/3 drugs, while the first biomarker DGM4, which predicts the efficacy of new drugs for psycho-diseases, has been discovered.
this series of breakthroughs has led to the simultaneous conduct of four international multi-center clinical trials, marking the beginning of explosive growth of soyuan organisms.
oversubscribed the financing to provide sufficient funds for the next phase of the development of SSO Bio and to further expand the foundation of the new drug pipeline.
, Chief Financial Officer of Soyuan Bio, said, "We are pleased that this round of financing has been approved by a number of leading investment institutions in the industry and has been successfully completed during the New Crown outbreak."
look forward to working closely with institutions in the capital process during periods of rapid biological development and significant growth.
" congratulates So yuan bio to complete nearly 600 million yuan C round of financing, hoping that with the help of capital, the company can bring these innovative drugs to market as soon as possible, benefiting patients.
.